19 - Even More Bad Bugs (with Limited Drugs)

Thursday, September 30, 2021

12:30 PM - 1:45 PM EDT

Moderator(s)

Belinda Ostrowsky, MD, MPH, FIDSA, FSHEA

Field Medical Officer
Centers for Disease Control & Prevention & Einstein/ Montefiore
New York, NY, United States

I do not have any relevant financial / non-financial relationships with any proprietary interests.
Yi Guo, PharmD, BCIDP

Co-director of Antimicrobial Stewardship
Montefiore Medical Center and Alert Einstein College of Medicine
New York, NY, United States

I do not have any relevant financial / non-financial relationships with any proprietary interests.

Speaker(s)

Jessica Howard-Anderson, MD, MSc

Assistant Professor
Emory University School of Medicine
Atlanta, GA, United States

I do not have any relevant financial / non-financial relationships with any proprietary interests.
Pavithra Srinivas, PharmD, BCPS, BCIDP, AAHIVP

Infectious Diseases/HIV Clinical Pharmacy Specialist
Truman Medical Centers, University Health Kansas City
Kansas City, MO, United States

Walgreens (Individual(s) Involved: Self): Shareholder

Participants should be aware of the following financial/non-financial relationships:

Belinda Ostrowsky, MD, MPH, FIDSA, FSHEA: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Yi Guo, PharmD, BCIDP: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Jessica Howard-Anderson, MD, MSc: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Pavithra Srinivas, PharmD, BCPS, BCIDP, AAHIVP: Walgreens (Individual(s) Involved: Self): Shareholder

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
ACPE Credits: ACPE 1.25 Knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-0000-21-001-H01-P

Learning Objectives:

At the conclusion of this session, participants will be able to:

review the recent literature and IDSA guidelines to translate this to practice tips for treatment of various infectious syndromes with extended spectrum beta lactamase (ESBL) Enterobacterales
review the recent literature and IDSA guidelines to translate this to practice tips for treatment of infections with Pseudomonas aeruginosa with Difficult to Treat Resistance (DTR- P. aeruginosa)

Presentations:

Difficult-to-treat Resistance (DTR) Pseudomonas Aeruginosa
Speaker: Jessica Howard-Anderson, MD, MSc – Emory University School of Medicine
Extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E)
Speaker: Pavithra Srinivas, PharmD, BCPS, BCIDP, AAHIVP – Truman Medical Centers, University Health Kansas City